Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: A systematic literature review

Annete Njue, Ann Colosia, Peter C. Trask, Robert Olivares, Shahnaz Khan, Adeline Abbe, Rachel Police, Jianmin Wang, Rodrigo Ruiz-Soto, James A. Kaye, Farrukh Awan

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


A systematic literature review was performed to collect and review information on the clinical efficacy and safety of treatments for relapsed/refractory (R/R) mantle cell lymphoma (MCL), with a meta-analysis, if possible. PubMed, Embase, and the Cochrane Library were searched for studies published in English from January 1, 1997, to August 2, 2012. Conference proceedings, bibliographic reference lists of included articles, recent reviews, and were searched for phase II to IV studies displaying results. Studies were included if they reported on patients with R/R MCL who were ineligible to receive high-dose chemotherapy with stem cell transplant. Studies of patients with several non-Hodgkin lymphoma subtypes were only included if they reported MCL outcomes separately. We identified 59 studies in R/R MCL. Forty distinct treatment regimens were evaluated. Thirty studies included more than 15 patients with R/R MCL. Six studies were comparative (including 5 randomized controlled trials [RCTs]); 53 were single-arm. There were no common treatments among the RCTs; therefore, a meta-analysis was not feasible. Thirty-one of 59 studies reported baseline data for patients with R/R MCL. Of the 30 studies with > 15 patients with R/R MCL, 30 reported overall response rate data, 14 reported progression-free survival (PFS), and 12 reported overall survival (OS). The small number of RCTs in R/R MCL precludes identifying an optimal treatment. Small sample sizes, infrequent reporting of OS and PFS, and limited information on patient characteristics made a comparison of results difficult. High-quality comparative studies of novel therapies that have the potential to demonstrate OS advantages in R/R MCL are needed.

Original languageEnglish (US)
Pages (from-to)1-12.e7
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number1
StatePublished - 2015
Externally publishedYes


  • Chemotherapy
  • MCL treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: A systematic literature review'. Together they form a unique fingerprint.

Cite this